REVB: Revelation Biosciences Growth-Adjusted Market Cap to Net Income

The PEG ratio for Revelation Biosciences (REVB) reflects market expectations, with the current parameter equal to 0.00. This trend is driven by the expansion of the Gemini product line aimed at combating kidney fibrosis. Management is focusing on innate immunity activation to attract partners, while business development remains independent of the macro cycle, relying exclusively on test results for the prevention of postoperative inflammation.

For Revelation Biosciences (REVB), which is focused on developing a single immune candidate, the PEG ratio reflects the balance between market valuation and the pace of profit scaling. This metric divides the P/E ratio by the EPS growth rate: a value below one signals that the asset is undervalued relative to its fundamental dynamics, which is critical for evaluating biotech startups.